HLA class-I-soluble antigen serum levels in liver transplantation

Puppo, Francesco; Pellicci, R; Brenci, Sabrina; Nocera, Arcangelo; Morelli, N; Dardano, Giovanni; Bertocchi, M.; Antonucci, Adelmo; Ghio, Massimo; Scudeletti, Marco; Barocci, S; Valente, Umberto; Indiveri, Francesco

doi:10.1016/0198-8859(94)90063-9

Cited by 43 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Enzyme-linked immunosorbent assay (ELISA) for sHLA class I. Soluble HLA class I levels were determined by double-determinant immunoassay, as previously described (9), with some modifications. Briefly, polystyrene ELISA plates (Immulon 4; Dynatech, Chantilly, VA) were coated with W6/32, monoclonal antibody to the monomorphic determinant of HLA class 1 antigens (10 p g h l in phosphate buffered saline [PBS], pH 7.4).…”

Section: Methodsmentioning

confidence: 99%

Elevated serum level of soluble HLA class I antigens in patients with systemic lupus erythematosus

Tsuchiya

Shiota

Yamaguchi

et al. 1996

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. To examine the clinical significance of serum soluble HLA class I antigens (sHLA class I) in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).Methods. Serum levels of sHLA class I were measured by enzyme-linked immunosorbent assay, using a monoclonal antibody against monomorphic determinant of HLA class I (W6/32) and an enzyme-labeled polyclonal antibody to human h-microglobulin.Results . Conclusion. Serum sHLA class I may be useful as a disease activity marker of SLE. The mechanism of secretion and the physiologic role of sHLA class I require further study.The soluble form of HLA class I antigens can be detected in serum. Elevation of the serum concentration of soluble HLA class 1 (sHLA class I) has been

show abstract

Section: Methodsmentioning

confidence: 99%

Elevated serum level of soluble HLA class I antigens in patients with systemic lupus erythematosus

Tsuchiya

Shiota

Yamaguchi

et al. 1996

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…It is possible that they are both shed from the membrane of damaged or lysed cells and secreted from activated immune cells. In fact, the serum levels of sHLA-I and sHLA-II increase during acute rejection episodes following organ transplant [3][4][5][6] and acute graft-versus-host disease following bone marrow transplantation [6,7], as well as during phenomena involving immune activation, like infectious [6,8] and autoim-mune diseases [9]. Furthermore, it has been reported that sHLA-I and sHLA-II may play an immunomodulatory role, mainly by downregulating activated immune cells [10].…”

Section: Introductionmentioning

confidence: 99%

Soluble HLA Class I and Class II Molecule Levels in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients

et al. 1997

Self Cite

View full text Add to dashboard Cite

Increased concentrations of soluble HLA class I and class II molecules (sHLA-I and sHLA-II) have been observed in infectious, inflammatory, and autoimmune diseases. Because autoimmune mechanisms are considered to play a role in the pathogenesis of multiple sclerosis (MS), we decided to dose sHLA-I and sHLA-II in serum and cerebrospinal fluid (CSF) of MS patients comparing their concentrations with those observed in serum and CSF of patients with other neurologic diseases (OND) without evidence of neuroradiologic involvement of central nervous system (CNS) and in serum of healthy donors. The serum concentrations of sHLA-I were higher in both MS and OND patients than in healthy donors (P < 0.05) whereas sHLA-II serum concentrations were lower in MS patients than in both OND patients and healthy donors (P < 0.01). Detectable amounts of sHLA-II were observed in the CSF of 45% of MS patients and in CSF of only 6% of OND patients (P < 0.001). In MS patients a significant correlation between sHLA-I serum and CSF concentrations was observed (P < 0.01), whereas sHLA-II serum and CSF levels did not correlate. In conclusion, alterations of sHLA-I and sHLA-II serum and CSF concentrations are present in MS patients and could be involved in the induction of enhanced susceptibility to develop MS or in MS pathogenesis.

show abstract

“…Following depletion of sHLA by magnetic immunoaffinity, Suciu-Foca et al [138], could identify anti-HLA-antibodies in 57% of the sera obtained from patients undergoing chronic rejection of kidney allografts compared with the 41% identified prior to antigen depletion, thereby confirming the presence of HLA antigen/ antibody complexes in patients' sera. The primary role of the HLA antibodies may be to clear the sHLA from the circulation of the host-so anti-HLA antibodies may be generated to perform the function, some of which could be DS anti-HLA antibodies and others non-donor-specific.…”

Section: Donor Specific Shla In Allograft Recipientsmentioning

confidence: 95%

“…Donor-specific sHLA elicits donor-specific anti-HLA antibodies: The presence of HLA antigen/anti-HLA-antibody immune complexes in patients' sera was positively associated with chronic humoral rejection (p < 0.0001) [138]. Following depletion of sHLA by magnetic immunoaffinity, Suciu-Foca et al [138], could identify anti-HLA-antibodies in 57% of the sera obtained from patients undergoing chronic rejection of kidney allografts compared with the 41% identified prior to antigen depletion, thereby confirming the presence of HLA antigen/ antibody complexes in patients' sera.…”

Section: Donor Specific Shla In Allograft Recipientsmentioning

confidence: 99%